Lantheus Stock (NASDAQ:LNTH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$107.98

52W Range

$50.20 - $126.89

50D Avg

$108.15

200D Avg

$83.89

Market Cap

$8.02B

Avg Vol (3M)

$638.90K

Beta

0.50

Div Yield

-

LNTH Company Profile


Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

834

IPO Date

Jun 25, 2015

Website

LNTH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Strategic Partnerships And Other$51.88M$46.87M$25.30M
DEFINITY$279.77M$244.99M$232.76M
License and Royalty Revenues$33.36M$48.02M$24.85M
Other Precision Diagnostics$22.98M$22.82M$26.97M
Techne Lite$87.37M$88.86M$91.29M
Total Precision Diagnostics$390.12M$356.68M$351.02M
Other Radiopharmaceutical Oncology$3.13M$4.10M$5.47M
PYLARIFY$851.30M$527.40M$43.41M
Product$1.26B--
Radiopharmaceutical Oncology$854.43M$531.51M$48.89M
Product Revenue, Net-$887.04M$400.36M

Fiscal year ends in Dec 23 | Currency in USD

LNTH Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.30B$935.06M$425.21M
Operating Income$364.64M$-13.44M$-76.09M
Net Income$326.66M$28.07M$-71.28M
EBITDA$444.18M$34.49M$-83.44M
Basic EPS$4.79$0.41$-1.06
Diluted EPS$4.65$0.40$-1.06

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 31, 24 | 12:18 PM
Q1 24May 02, 24 | 12:00 AM
Q4 23Feb 22, 24 | 3:24 PM

Peer Comparison


TickerCompany
RDYDr. Reddy's Laboratories Limited
ANIPANI Pharmaceuticals, Inc.
AQSTAquestive Therapeutics, Inc.
DVAXDynavax Technologies Corporation
NBIXNeurocrine Biosciences, Inc.
IRWDIronwood Pharmaceuticals, Inc.
DERMJourney Medical Corporation
DCPHDeciphera Pharmaceuticals, Inc.
ALKSAlkermes plc
PCRXPacira BioSciences, Inc.
COLLCollegium Pharmaceutical, Inc.
CTLTCatalent, Inc.
AVDLAvadel Pharmaceuticals plc
AMPHAmphastar Pharmaceuticals, Inc.